Literature DB >> 19776782

Lupus activation with cerebritis following pegylated interferon in a hemodialysis patient.

Sanjay Kumar Agarwal1, Charanjeet Lal, Sabahat Husain Zaidi.   

Abstract

BACKGROUND: A 20-year-old female patient with chronic hepatitis C virus infection and end-stage renal disease due to systemic lupus erythematosus was admitted to hospital with fever, pain in the abdomen, seizures and an alteration of consciousness. The patient was on maintenance dialysis and was receiving pegylated interferon monotherapy for her chronic hepatitis C virus infection. INVESTIGATIONS: Physical examination, laboratory tests including complete blood count and measurement of serum electrolyte levels, CT scans of the head and abdomen, MRI of the brain, microscopic examination of the cerebrospinal fluid, chest X-ray, echocardiography and measurement of C3 complement and anti-double-stranded DNA antibody levels. DIAGNOSIS: Activation of systemic lupus erythematosus with cerebritis following pegylated interferon therapy. MANAGEMENT: Intravenous fluid, intermittent oxygen, intravenous diphenylhydantoin, intravenous pulse methylprednisolone 500 mg for 3 days followed by 40 mg per day of oral prednisolone, and temporary withdrawal of pegylated interferon.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19776782     DOI: 10.1038/nrneph.2009.137

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  16 in total

1.  Lupus syndrome, hypothyroidism and bullous skin lesions after interferon alfa therapy for hepatitis C in a haemodialysis patient.

Authors:  Dominique Pouthier; Francois Theissen; René-Louis Humbel
Journal:  Nephrol Dial Transplant       Date:  2002-01       Impact factor: 5.992

2.  Nonconvulsive status epilepticus in peritoneal dialysis patients.

Authors:  K M Chow; A Y Wang; A C Hui; T Y Wong; C C Szeto; P K Li
Journal:  Am J Kidney Dis       Date:  2001-08       Impact factor: 8.860

3.  Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity.

Authors:  J S Cheigh; H Kim; K H Stenzel; L Tapia; J F Sullivan; W Stubenbord; R R Riggio; A L Rubin
Journal:  Am J Kidney Dis       Date:  1990-09       Impact factor: 8.860

Review 4.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

5.  Analysis of lupus activity in end-stage renal disease treated by hemodialysis.

Authors:  K Okano; W Yumura; K Nitta; K Uchida; T Ohnuki; A Kawashima; H Nihei
Journal:  Intern Med       Date:  2001-07       Impact factor: 1.271

Review 6.  Seizures in dialysis patients treated with recombinant erythropoietin. Review of the literature and guidelines for prevention.

Authors:  M Beccari
Journal:  Int J Artif Organs       Date:  1994-01       Impact factor: 1.595

7.  Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view.

Authors:  R Pellicano; A Smedile; S Peyre; M Astegiano; G Saracco; R Bonardi; M Rizzetto
Journal:  Minerva Gastroenterol Dietol       Date:  2005-03

8.  The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection.

Authors:  S C Akhan; B Kalender; M Ruzgar
Journal:  Infection       Date:  2008-07-15       Impact factor: 3.553

9.  Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C.

Authors:  Vincent Ho; Anna Mclean; Shaughan Terry
Journal:  J Clin Rheumatol       Date:  2008-06       Impact factor: 3.517

Review 10.  Autoimmune disease complicating antiviral therapy for hepatitis C virus infection.

Authors:  Leslie E Wilson; David Widman; Steven H Dikman; Peter D Gorevic
Journal:  Semin Arthritis Rheum       Date:  2002-12       Impact factor: 5.532

View more
  2 in total

Review 1.  Side effects of cytokines approved for therapy.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606

2.  Pegylated interferon monotherapy for hepatitis C virus infection in patients on hemodialysis: A single center study.

Authors:  S K Agarwal; D Bhowmik; S Mahajan; S Bagchi
Journal:  Indian J Nephrol       Date:  2016 Jul-Aug
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.